Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 9/2003

01.09.2003 | Original Article

Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT

verfasst von: Nicolas Aide, Olivier Cappele, Philippe Bottet, Henri Bensadoun, Armelle Regeasse, François Comoz, Franck Sobrio, Gérard Bouvard, Denis Agostini

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to assess the efficiency of fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the characterisation and primary staging of suspicious renal masses, in comparison with computed tomography, the current standard imaging modality. Fifty-three FDG PET studies were performed within the framework of a prospective study: 35 for both characterisation and staging of a suspicious mass, and 18 for staging early after surgical removal of a renal cancer. In the characterisation of renal masses, a high rate of false negative results was observed, leading to a sensitivity, specificity and accuracy of 47%, 80% and 51% respectively, versus 97%, 0/5 and 83% respectively for CT. FDG PET detected all the sites of distant metastasis revealed by CT, as well as eight additional metastatic sites, leading to an accuracy of 94% versus 89% for CT. However, 36/53 patients (68%) did not have any distant metastasis on either CT or on PET. All but one of these patients had a low Fuhrman histological grade and a limited local stage (≤pT2). We conclude that FDG PET does not offer any advantage over CT for the characterisation of renal masses but that it appears to be an efficient tool for the detection of distant metastasis in renal cancer. However, our data suggest that a selection process could be implemented to determine which patients should undergo PET. FDG PET could be performed in the event of a solitary metastasis or doubtful images on CT. Selection could also be based on adverse histological findings from nephrectomy specimens in order to perform staging early after nephrectomy.
Literatur
1.
Zurück zum Zitat Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2:157–164.PubMed Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001; 2:157–164.PubMed
2.
Zurück zum Zitat Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-d-glucose: pilot animal and human studies. J Urol 1991; 146:1470–1474.PubMed Wahl RL, Harney J, Hutchins G, Grossman HB. Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-d-glucose: pilot animal and human studies. J Urol 1991; 146:1470–1474.PubMed
3.
Zurück zum Zitat Kocher F, Geimmel S, Hauptmann R, Reske S. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35:223P. Kocher F, Geimmel S, Hauptmann R, Reske S. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm. J Nucl Med 1994; 35:223P.
4.
Zurück zum Zitat Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996; 35:146–150.PubMed Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A 1996; 35:146–150.PubMed
5.
Zurück zum Zitat Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510–515.PubMed Goldberg MA, Mayo-Smith WW, Papanicolaou N, Fischman AJ, Lee MJ. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510–515.PubMed
6.
Zurück zum Zitat Montravers F, Grahek D, Kerrou K, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41:78–84.PubMed Montravers F, Grahek D, Kerrou K, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41:78–84.PubMed
7.
Zurück zum Zitat Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825–830.PubMed Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825–830.PubMed
8.
Zurück zum Zitat Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1707–1723.PubMed Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001; 28:1707–1723.PubMed
9.
Zurück zum Zitat Agostini D, Bensadoun H, Rabut B, Bottet P, Aide N, Derlon JM. New 3D whole body PET imaging to detect metastatic renal cancer with18F-FDG. J Nucl Med 2001; 42:288P. Agostini D, Bensadoun H, Rabut B, Bottet P, Aide N, Derlon JM. New 3D whole body PET imaging to detect metastatic renal cancer with18F-FDG. J Nucl Med 2001; 42:288P.
10.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655–663.PubMed Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655–663.PubMed
11.
Zurück zum Zitat Amendola MA, Bree RL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988; 166:637–641.PubMed Amendola MA, Bree RL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988; 166:637–641.PubMed
12.
Zurück zum Zitat Miyauchi T, Brown RS, Grossman HB, Wojno K, Wahl RL. Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. J Nucl Med 1996; 37:64P. Miyauchi T, Brown RS, Grossman HB, Wojno K, Wahl RL. Correlation between visualization of primary renal cancer by FDG-PET and histopathological findings. J Nucl Med 1996; 37:64P.
13.
Zurück zum Zitat Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9:15–18.CrossRefPubMed Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9:15–18.CrossRefPubMed
14.
Zurück zum Zitat Montravers F, Rousseau C, Doublet JD, et al. In vivo inaccessibility of somatostatin receptors to111In-pentreotide in primary renal cell carcinoma. Nucl Med Commun 1998; 19:953–961.PubMed Montravers F, Rousseau C, Doublet JD, et al. In vivo inaccessibility of somatostatin receptors to111In-pentreotide in primary renal cell carcinoma. Nucl Med Commun 1998; 19:953–961.PubMed
15.
Zurück zum Zitat Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26:226–230.CrossRefPubMed Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26:226–230.CrossRefPubMed
16.
Zurück zum Zitat Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001; 40:252–255.PubMed Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur Urol 2001; 40:252–255.PubMed
17.
Zurück zum Zitat Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol 1995; 2:71–76.PubMed Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol 1995; 2:71–76.PubMed
18.
Zurück zum Zitat Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655–1659.CrossRefPubMed Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655–1659.CrossRefPubMed
19.
Zurück zum Zitat Ficarro V, Righetti R, Pilloni S, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 2002; 41:190–198.CrossRefPubMed Ficarro V, Righetti R, Pilloni S, et al. Prognostic factors in patients with renal cell carcinoma: retrospective analysis of 675 cases. Eur Urol 2002; 41:190–198.CrossRefPubMed
20.
Zurück zum Zitat Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1–pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002; 94:2590–2595.CrossRefPubMed Minervini A, Lilas L, Minervini R, Selli C. Prognostic value of nuclear grading in patients with intracapsular (pT1–pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer 2002; 94:2590–2595.CrossRefPubMed
Metadaten
Titel
Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT
verfasst von
Nicolas Aide
Olivier Cappele
Philippe Bottet
Henri Bensadoun
Armelle Regeasse
François Comoz
Franck Sobrio
Gérard Bouvard
Denis Agostini
Publikationsdatum
01.09.2003
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-003-1211-4

Weitere Artikel der Ausgabe 9/2003

European Journal of Nuclear Medicine and Molecular Imaging 9/2003 Zur Ausgabe